For decades, histone deacetylase (HDAC) inhibitors have been heralded as promising cancer therapeutics due to their ability to block HDAC enzymes, which were long believed to fuel cancer progression by altering gene expression. However, groundbreaking research from Baylor College of Medicine and its collaborators now challenges this entrenched paradigm, revealing a far more complex interaction between HDAC inhibitors and cancer biology. This novel study, published in the journal Signal Transduction and Targeted Therapy, advocates for a critical reassessment of the molecular mechanisms through which these inhibitors exert their therapeutic effects, urging the scientific community to look beyond HDAC enzyme inhibition to uncover other potential anticancer targets.
At the heart of HDAC inhibitors’ assumed mode of action lies the epigenetic regulation of gene activity via modifications on histones — protein complexes around which DNA is tightly coiled inside the cell nucleus. Chemical tags like acetyl groups regulate how accessible DNA is for transcriptional machinery, thereby controlling which genes are actively expressed. HDAC enzymes remove these acetyl groups, condensing chromatin and generally repressing gene expression. Consequently, HDAC inhibitors are thought to increase histone acetylation, loosening chromatin structure and promoting the expression of genes that could suppress tumor growth or trigger cancer cell death.
Yet, this classical narrative is contradicted by emerging data suggesting that HDACs do not universally act as cancer promoters. In some cellular contexts, HDACs may function as tumor suppressors, a paradox that complicates our understanding of their biological roles. Moreover, experiments have shown that while HDAC inhibitors can augment histone acetylation levels, corresponding changes in gene expression are sometimes unexpectedly moderate, failing to align with the anticipated broad epigenetic remodeling.
The latest study, led by Dr. Zheng Sun, associate professor at Baylor and a member of the Dan L Duncan Comprehensive Cancer Center, employs an arsenal of unbiased computational bioinformatics analyses to interrogate relationships between HDAC expression levels, various cancer types, and patient outcomes. These investigations reveal a striking lack of consistent correlation; different HDAC isoforms and their abundance do not uniformly associate with cancer progression or overall survival, suggesting a far more nuanced interaction than previously appreciated.
Adding a decisive twist, the research team explored the effects of the HDAC inhibitor FK228 in mouse models of solid tumors frequently targeted in clinical trials. Surprisingly, when they genetically eliminated the ability of FK228 to inhibit its primary HDAC enzyme targets, the compound retained most of its anticancer efficacy. This dissociation between enzyme inhibition and therapeutic effect fundamentally challenges the dogma that HDAC enzymatic activities are the universal anti-cancer targets of these inhibitors.
These results provoke a paradigm shift in the field, raising the possibility that HDAC inhibitors may exert anti-cancer effects through off-target interactions with other proteins or pathways. The idea that such non-HDAC targets might mediate tumor suppression invites intensive future research to identify these alternate molecular players, which could themselves become promising drug targets, ultimately enabling more precise and effective therapies.
Understanding the multifaceted mechanism of HDAC inhibitors demands intricate chemical biology and proteomic interrogation to unveil other proteins or complexes bound or modulated by these compounds. This approach could uncover a hidden network of molecular interactions that contribute to the observed anticancer activity, illuminating new pathways of cancer vulnerability.
Beyond HDACs’ canonical role in histone deacetylation, the inhibitors may affect non-histone substrates, altering processes like protein stability, transcription factor activity, or DNA repair. Such diverse biological effects could partly explain why HDAC inhibitors exhibit varied efficacy and toxicity profiles in different cancer types and patient cohorts.
The ramifications of this study extend into the clinical domain, where HDAC inhibitors are currently employed or trialed, including hematologic malignancies and solid tumors. A refined molecular understanding will aid in patient stratification, allowing clinicians to predict who will benefit from treatment and to design combination regimens targeting complementary pathways for maximal cancer cell eradication.
Critically, this work underscores the importance of moving beyond traditional one-target drug development models toward systems-level biology approaches that consider polypharmacology as both a challenge and an opportunity in cancer therapeutics. HDAC inhibitors may serve as prototypes for a new generation of multi-targeted epigenetic modulators with tailored specificity profiles informed by molecular and phenotypic data.
Dr. Chaitra Rai, the study’s first author and a postdoctoral fellow within the Sun laboratory, emphasizes the necessity of reexamining simplistic assumptions. She highlights that relying solely on enzyme inhibition as a surrogate biomarker for drug efficacy may overlook crucial aspects of drug action, leading to suboptimal clinical outcomes and an incomplete understanding of resistance mechanisms.
Ultimately, this comprehensive investigation lays the groundwork for redefining the therapeutic landscape of HDAC inhibitors. By integrating computational modeling, molecular biology, and in vivo experimental systems, this research illuminates the complexity of cancer pharmacology and opens pathways for innovative interventions that transcend existing frameworks.
In conclusion, the discovery that HDAC enzyme activity is not the universal anticancer target of HDAC inhibitors not only reshapes fundamental scientific knowledge but also paves the way for developing next-generation epigenetic therapies. These findings compel researchers and clinicians alike to embrace a broader view of drug actions, potentially revolutionizing cancer treatment strategies in the years to come.
Subject of Research: Not applicable
Article Title: Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors.
News Publication Date: 5-Jun-2026
Web References:
Publication DOI: 10.1038/s41392-026-02698-1
Journal: Signal Transduction and Targeted Therapy
Keywords: Histone deacetylase, HDAC inhibitors, cancer therapeutics, epigenetics, gene expression, FK228, bioinformatics, tumor suppressors, polypharmacology, drug mechanisms, cancer biology, molecular targets
Tags: Baylor College of Medicine cancer studiescancer epigenetics research 2024chromatin remodeling in cancercomplexities of HDAC inhibitors effectsepigenetic regulation of gene expressionHDAC enzyme inhibition mechanismshistone acetylation and tumor suppressionhistone deacetylase inhibitors in cancer therapymolecular basis of HDAC inhibitor actionnovel targets for anticancer drugsrethinking cancer drug developmentsignal transduction in targeted therapy
